Reduce forward and sideways leaning
- Trial ID
- NCT07010328
- Official Title
- Efficacy of Integrating Artificial Intelligence Solutions in Rehabilitation in Postural Trunk Disorders in Parkinson's Disease.
- Goal
- Reduce forward and sideways leaning
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- IRCCS National Neurological Institute "C. Mondino" Foundation
- Study Type
- INTERVENTIONAL
- Enrollment
- 20 participants
- Conditions
- Parkinson Disease, Physical Inactivity, Physical Disability, Pisa Syndrome
- Interventions
- Neurorehabilitation, AI-based home rehabilitation for postural disorders
Plain-Language Summary
The goal is to reduce abnormal forward or sideways bending of the trunk, namely camptocormia and Pisa syndrome, to improve posture, balance and daily function in people with Parkinson's. The approach uses an AI-guided home neurorehabilitation program that tracks trunk angles with sensors or camera-based analysis, gives real-time feedback, and personalizes strengthening, stretching and posture-training exercises, used alongside usual Parkinson's medications like levodopa rather than replacing them. The trial is looking for adults 18 and older with Parkinson's at Hoehn and Yahr stage I to III who have camptocormia (≥30°) or Pisa syndrome (≥10°) and an MMSE over 23, excluding those with atypical parkinsonism, prior spinal surgery or major spinal disease, other neurological conditions, or severe dyskinesias.
Locations
- IRCCS Mondino Foundation, Pavullo nel Frignano, Pavia, Italy
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Neurorehabilitation. The goal is to reduce abnormal forward or sideways bending of the trunk, namely camptocormia and Pisa syndrome, to improve posture, balance and daily function in people with Parkinson's. The approach uses an AI-guided home neurorehabilitation program that tracks trunk angles with sensors or camera-based analysis, gives real-time feedback, and personalizes strengthening, stretching and posture-training exercises, used alongside usual Parkinson's medications like levodopa rather than replacing them. The trial is looking for adults 18 and older with Parkinson's at Hoehn and Yahr stage I to III who have camptocormia (≥30°) or Pisa syndrome (≥10°) and an MMSE over 23, excluding those with atypical parkinsonism, prior spinal surgery or major spinal disease, other neurological conditions, or severe dyskinesias.
- Who can participate?
- Participants must be at least 18 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 3 years and 3 months.